Sex: F
Vaccine: RAB, RAB
Symptoms: Immunoglobulin therapy, Interchange of vaccine products, Lymphadenopathy, Nasal congestion, Nasopharyngitis
Clinical narrative: cold-like symptoms like sore throat and congestion; cold-like symptoms like sore throat and congestion; Swollen lymph nodes; Received two doses of Rabavert and one dose of another brand that they had in stock; Case reference number US-BN-2022-001076 is a spontaneous case report initially received on 12-May-2022 from a consumer via Communication (reference number: USBAV22-0181) and concerns a female patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.  On unspecified day, the patient was vaccinated with the first dose of RabAvert (Rabies Virus (Inactivated, Strain Flury LEP) (PCEC)); batch number: unknown) at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration, for post-exposure prophylaxis due to a bat bite. As reported, the patient received the immune globulin as well.  On unspecified day, an unknown amount of time after the first dose, the patient was vaccinated with the second dose of RabAvert (batch number: unknown) at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration.  On unspecified day, an unknown amount of time after the first dose, the patient was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) at an unknown dose, route or site of administration (explicitly coded as 'Interchange of vaccine products'), for post-exposure prophylaxis due to a bat bite.  On unspecified date, an unknown amount of time after the last dose of RabAvert, the patient experienced a swollen lymph node.   On unspecified date, an unknown amount of time after the first dose, the patient was vaccinated with the third dose of RabAvert (batch number: unknown); at a dose reported as 2.5 international units, administered intramuscularly, at unknown site of administration.  *On unspecified date, three weeks after the rabies vaccine, the patient developed cold-like symptoms, like sore throat and congestion. *  *At the time of this report the outcome of the events was unknown.*  *The reporter assessed the events as non serious and as possibly related to RabAvert vaccine.*   Additional information received from Communication on 13-May-2022 included vaccination details for two doses of RabAvert and additional co-suspect vaccine.  Additional information received from Communication on 16-May-2022 included third dose of RabAvert. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information was received on 07-Jun-2022: New information included new events.  Additional information received on 08-Jun-2022 included local case ID.  Additional information received on 13-Jun-2022 included updated local case ID.  This case is linked to cases no. US-BN-2022-001075, US-BN-2022-001077, US-BN-2022-001090 (the same reporter).; Reporter's Comments: A female patient of unspecified age was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) after receiving 2 doses of RabAvert for post-exposure prophylaxis due to a bat bite, which is considered as interchange of vaccine products. On unspecified date, an unknown amount of time after the last dose of RabAvert, the patient experienced a swollen lymph node. Reportedly, three weeks after the rabies vaccine, the patient developed cold-like symptoms, like sore throat and congestion. Lymphadenopathy is listed, while nasal congestion and throat sore are unlisted for RabAvert according to the guidelines. Interchange of vaccine products is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. The outcome of the event was unknown, as reported. Considering the absence of confounding factors and since the contributory role of the suspect vaccine cannot be excluded, lymphadenopathy, nasal congestion and sore throat have been considered as related to RabAvert. Interchange of vaccine products has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age was vaccinated with a dose of Rabies vaccine (brand name unknown, as reported other brand name) after receiving 2 doses of RabAvert for post-exposure prophylaxis due to a bat bite, which is considered as interchange of vaccine products. On unspecified date, an unknown amount of time after the last dose of RabAvert, the patient experienced a swollen lymph node. Reportedly, three weeks after the rabies vaccine, the patient developed cold-like symptoms, like sore throat and congestion. Lymphadenopathy is listed, while nasal congestion and throat sore are unlisted for RabAvert according to the guidelines. Interchange of vaccine products is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. The outcome of the event was unknown, as reported. Considering the absence of confounding factors and since the contributory role of the suspect vaccine cannot be excluded, lymphadenopathy, nasal congestion and sore throat have been considered as related to RabAvert. Interchange of vaccine products has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.